Nucleome Therapeutics appoints Nigel Clark as Main Business Officer

Nucleome Therapeutics appoints Nigel Clark as Chief Business Officer

Nigel brings 20+ decades of industrial and senior managerial experience in the biotech and pharma market

Oxford, British isles, 15 February 2022 – Nucleome Therapeutics, a biotechnology firm decoding the dark make a difference of the human genome to uncover novel strategies to handle sickness, these days announces the appointment of Dr Nigel Clark as Main Business enterprise Officer with instant effect. Nigel has extra than 20 a long time of offer-building practical experience from negotiating and executing in excess of 20 big transactions well worth over $1.6bn.

Most lately, Nigel served as Senior Vice President of Organization Advancement at Kymab, which was acquired by Sanofi in 2021. In his purpose at Nucleome, Nigel will serve on the government management staff and will shape and oversee Nucleome’s company and corporate development method.

“Nigel has wide commercial encounter, an outstanding file of substantial value transactions and very long-standing relationships across the lifetime sciences sector. I am thrilled to welcome him to our executive workforce,” commented Dr Danuta Jeziorska, Main Executive Officer and Founder of Nucleome. “He joins us at an exceptionally enjoyable stage as we go on to decode the dim genome to uncover precision medicines and commenced organic validation of our initial targets with the ambition to development them to discovery programmes for the remedy of autoimmune illnesses.”

Dr Nigel Clark, Main Organization Officer of Nucleome, mentioned: “The option to be a part of Nucleome Therapeutics, a organization with actual possible to change drug discovery and translational medication, is definitely interesting. I have been privileged in my career to date to work with the quite best in the business and I appear forward to doing work with the extraordinary government and scientific group at Nucleome to realise a paradigm change in the exploration and progress of novel therapeutics to improve patient’s lives.”

Dr Nigel Clark most just lately served as SVP Business enterprise Growth and a member of the executive group at Kymab which was divested in 2021 to Sanofi for $1.1bn upfront and a even further $300M of results-centered milestones. Past roles include things like Main Business Officer at Syntaxin (divested to Ipsen Pharma), VP of Company Advancement at Vernalis and a member of the senior government committee as properly as President, Vernalis Canada. Nigel has also held management roles at Ribotargets and British Biotech and was co-head of the biotech small business unit at Datamonitor. He was awarded a Ph.D. from the College of Looking at for investigation performed into HIV gene regulation and completed his scientific education as a put up-doctoral scientist at the office of biochemistry, University of Oxford.

Story proceeds

– Close –

About Nucleome Therapeutics
Nucleome Therapeutics is decoding the dim subject of the human genome to uncover novel strategies to address disorder. The dark genome retains more than 90% of illness-linked genetic variants whose worth continues to be untapped, symbolizing a important prospect for drug discovery and advancement. We have the distinctive capability to website link these variants to gene function and map disease pathways. Our cell style-distinct system results in significant resolution 3D genome framework maps and enables variant useful validation at scale in most important cell kinds. This enables us to explore and develop novel, improved and safer medicines. The original target of the enterprise is on lymphocytes and connected autoimmune illness. Our ambition is to create a strong pipeline of drug property, with corresponding biomarkers. Nucleome Therapeutics was founded by major specialists in gene regulation from the College of Oxford and backed by financial investment from Oxford Sciences Innovation. For additional information, be sure to stop by www.nucleome.com.

For much more info, you should get hold of:

Nucleome Therapeutics
Dr Danuta Jeziorska, Chief Govt Officer & Founder
get in touch [email protected]

Consilium Strategic Communications
Mary-Jane Elliott/ Sukaina Virji/ Lindsey Neville
[email protected]